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A b s t r a c t
Measurement o f  circulating B-type natriuretic 
peptide (BNP) and N-terminal proBNP (NT-proBNP) 
can identify patients with heart failure and guide 
therapy. The limit o f  detection, linearity, imprecision, 
method comparison, analytic concordance, and 
reference intervals o f  the A ccess 2  BN P (Biosite, San 
Diego, CA), AD VIA Centaur BN P (Bayer Diagnostics, 
Tarrytown, NY), A xSY M  BN P (Abbott Diagnostics, 
Abbott Park, IL), and E l  70 NT-proBNP (Roche 
Diagnostics, Indianapolis, IN) methods were evaluated. 
The Triage meter BN P assay (Biosite) was the 
comparison method. Imprecision testing showed total 
coefficients o f  variation o f  4 .1% , 4.4%}, 5.5%, and 0 .8 %  
fo r  the A ccess 2, AD VIA Centaur, AxSYM , and E l  70, 
respectively. Relative to the Triage meter, method  
comparison revealed a slope o f  0 .96  and r = 0.95, a 
slope o f  0 .7 7  and r = 0.92, a slope o f  1 .13 and r = 0.94, 
and a slope o f  8 .8  and r = 0 .8 0  fo r  the A ccess 2, ADVIA  
Centaur, AxSYM , andE 170, respectively. Overall 
analytic concordance values with the Triage meter were 
95.9% , 92 .9% , 92 .4% , and 8 4 .3 %  fo r  the A ccess 2, 
AD VIA Centaur, AxSYM, and E 170, respectively All 
automated natriuretic peptide methods showed  
acceptable analytic performance.
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B-type natriuretic peptide (BNP) is a neurohormone that 
is synthesized in the ventricles of the heart as a 134-amino- 
acid polypeptide known as preproBNP, which is cleaved to 
produce proBNP (108 amino acids) and an N-terminal signal 
peptide (26 amino acids). ProBNP is cleaved to the inactive N- 
terminal proBNP (NT-proBNP) fragment (amino acids 1-76) 
and the hormone, BNP (amino acids 77-108).1 The release of 
BNP and NT-proBNP is dependent on ventricular myocyte 
stretch in response to ventricular- volume expansion. 
Measurements of BNP and NT-proBNP have been used to 
identify patients with heart failure and to monitor the efficacy 
of their treatment.2 At present, there are an estimated 5 million 
Americans with heart failure, and nearly 50,000 new cases are 
diagnosed every year-.3
Human BNP (BNP 1-32) is biologically active and is com­
posed of the last 32 amino acids of the carboxyl terminus of 
proBNP. It has a relatively short circulating half-life of 20 min­
utes.1 Studies have shown that there may be more than one form 
of circulating BNP.4 Proteolytic degradation can occur- in vivo 
with production of small amounts of des-SerPro-BNP (3-32). In 
vitro, EDTA-anticoagulated plasma collected in glass tubes can 
produce the active protease, kallikrein, with consequent loss of 
amino acids from the C.-terminus of BNP.5 Prolonged incuba­
tion of EDTA-anticoagulated plasma collected in plastic tubes 
produces des-SerPro-BNP owing to proteolytic degradation of 
the N-terminus. Presumably an aminopeptidase is involved in 
this process.4 NT-proBNP comprises the first 76 amino acids of 
proBNP and is cosecreted with BNP. It is biologically inactive 
and relatively stable in circulation and in serum in vitro.6 The 
circulating half-life is 1 to 2 hour's.1
A number of commercially available automated assays for 
BNP and NT-proBNP measurement have become available:
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the Access 2 BNP (Biosite, San Diego, CA), ADVIA Centaur 
BNP (Bayer Diagnostics, Tarrytown, NY), AxSYM BNP 
(Abbott Diagnostics, Abbott Park, IL), and Elecsys NT- 
proBNP assays (Roche Diagnostics, Indianapolis, IN).7"10 
These 4 automated methods were evaluated for limit of detec­
tion, linearity, imprecision, and reference intervals. Method 
comparison studies also were performed in which the Triage 
point-of-care immunoassay (Biosite) was used as the compar­
ison method and analytic concordance was assessed.11-12
M a t e r ia ls  a n d  M e t h o d s
The Access 2 BNP immunoassay, the ADVIA Centaur 
BNP immunoassay, a microparticle enzyme BNP immunoas­
say (Axis Shield Diagnostics, Dundee, Scotland) performed 
on the AxSYM, and the MODULAR ANALYTICS E170 NT- 
proBNP immunoassay (Roche Diagnostics) automated meth­
ods were evaluated. The Triage BNP immunoassay (Biosite) 
performed on the Triage meter (Biosite) was used as the com­
parison method. All analyses were performed according to the 
manufacturers’ instructions.
The limit o f detection for each of the automated natriuret­
ic peptide methods was determined by performing 2 separate 
runs and averaging the results. In each run “ zero” material, as 
specified later in this paragraph, was analyzed in 10 replicates, 
nonzero material was analyzed in 3 replicates as required by 
EP Evaluator Release 5 software (David G. Rhoads 
Associates, Kennett Square, PA), and the 2 SD limit of the 
zero material was calculated. On the Access 2, BNP Calibrator 
SO (0 ng/L) and Calibrator S2 (111 ng/L; Biosite) were used. 
On the ADVIA Centaur, Multi-diluent 1 (0 ng/L) and Master 
Curve Material Level 3 (72 ng/L; Bayer Diagnostics) were 
used. On the AxSYM, BNP Calibrator A  (0 ng/L) and 
Calibrator B (100 ng/L; Axis Shield Diagnostics) were used. 
On the E170, Universal Diluent (0 ng/L) and PreciControl 
proBNP2 diluted 1:2 with Universal Diluent (final concentra­
tion, 140 ng/L; Roche Diagnostics) were used.
Lineaiity was assessed on the Access 2 by performing 
serial dilutions of BNP Calibrator S5 with Calibrator SO 
(Biosite). Calibrator S5 was diluted to give final concentra­
tions of 0.8%, 2%, 5%, 10%, 20%, 40%, 80%, and 100% of 
the original (range of BNP concentrations, 42-4,916 ng/L). 
For the ADVIA Centaur, lineaiity was assessed by making 
serial dilutions of Master Curve Material Level 7 with Multi­
diluent 1 (Bayer Diagnostics). Master Curve Material Level 7 
was diluted with Multi-diluent 1 to give final concentrations 
of 0.78%, 1.56%, 3.125%, 6.25%, 12.5%, 25%, 50%, 84%, 
and 100% of the original (range of BNP concentrations, 42­
4,298 ng/L). For the AxSYM, lineaiity was assessed by per­
forming serial dilutions of BNP Calibrator F with BNP 
Calibrator A  with final dilutions of 1%, 2.5%, 6.25%, 12.5%,
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25%, 50%, and 90% of the original (range of BNP concentra­
tions, 40-3,671 ng/L). For the E170, proBNP CalC.heck Level 
3 was diluted serially with Universal Diluent to give final dilu­
tions of 0.105%, 0.21%, 0.52%, 1.04%, 2.08%, 4.17%, 
8.33%, 16.67%, 25%, 50%, and 100% of the original (range 
of NT-proBNP concentrations, 42-20,974 ng/L). All samples 
were assayed in duplicate for each analyzer.
Imprecision studies were performed with the Access 2, 
ADVIA Centaur, AxSYM, and E170 using individual manu­
facturers’ quality control material. Three concentrations of 
lyophilized BNP Controls for the ADVIA Centaur and 2 con­
centrations of NT-proBNP PreciC.ontrols for the E170 were 
reconstituted according to package insert instructions. 
Multiple bottles for each level were pooled and divided into 
aliquots for daily use. All aliquots were stored frozen at -70°C 
until use. Liquid Access 2 (Biosite) and AxSYM BNP controls 
were stored at 4°C. Controls were assayed by each method in 
replicates of 2 using fresh controls for each run. Two runs 
were conducted per day, on each of 5 days, with a minimum 
of 2 hours separating each run for a total of 20 replicates for 
each control level.
For method comparison studies, EDTA-anticoagulated 
plasma specimens submitted for BNP testing were obtained 
from -20°C frozen storage following completion of clinical 
testing. Specimens chosen contained BNP concentrations that 
spanned a concentration range of 6 to 4,730 ng/L by the Triage 
meter. The subjects were between 5 and 104 years old. On 
retrieval, samples were stored at -20°C for up to 2 weeks and 
then moved to -70°C storage until analysis. Before analysis 
samples were thawed, mixed thoroughly at low speed, and 
centrifuged at 2,000),' for 10 minutes to remove any particulate 
matter. A  total of 197 samples were analyzed by the Access 2, 
ADVIA Centaur, AxSYM, E170, and Triage meter methods. 
All testing was carried out according to manufacturers’ speci­
fications.
To verify reference intervals, EDTA-anticoagulated plas­
ma specimens from apparently healthy subjects who were not 
taking any prescription medications were retrieved from 
-70°C storage and assayed by each automated method. The 
sample population consisted of 60 men and 60 women 
between 19 and 61 years of age, with a median age of 30 
years. All samples were subjected to the same handling proce­
dures before analysis by each method. All studies using sam­
ples obtained from humans were approved by the institution­
al review board of the University of Utah, Salt Lake City.
Epitope-mapping studies were performed using the 
Access 2, AxSYM, and ADVIA Centaur BNP methods. Five 
different human BNP fragments were synthesized at the 
University of Utah Health Sciences Center Core Research 
Facility, Salt Lake City, and contained the following amino 
acid sequences: 1-32, 3-32,4-32, 10-32, and 1-31. These pep­
tides were purified by reverse phase high-performance liquid
© American Society for Clinical Pathology
Clinical Chemistry / Original Article
chromatography and cyclized by reduction and oxidation to 
form a disulfide bond between the cysteines at positions 10 
and 26. A second purification step was performed after 
cyclization by reverse phase high-performance liquid chro­
matography, and the purity of each peptide was confirmed by 
mass spectrometry. Lyophilized peptide fragments were dis­
solved in a 1:1 solution of dimethyl sulfoxide and water and 
stored at ~70°C. Synthetic peptides were quantified by amino 
acid analysis after acid hydrolysis. For epitope-mapping stud­
ies, each of the synthetic peptides was diluted in a protein- 
containing diluent provided by Abbott Diagnostics to 
1:500,000 and 1:1,000,000 dilutions using volumetric glass­
ware. A sample of the diluent and aliquots of the diluted pep­
tides were ran in duplicate on the Access 2, AxSYM, and 
ADV1A Centaur BNP assays. BNP concentrations were cal­
culated by subtracting the average diluent concentration from 
the average of the concentrations measured for each dilution 
of each peptide. The percentages of recovery were determined 
based on the molar concentrations of peptide diluted in the 
matrix according to quantification by amino acid analysis.
EP Evaluator Release 5 software was used for limit of 
detection calculations, linearity assessment, complex impreci­
sion calculations, reference interval determinations, and diag­
nostic concordance. Passing-Bablok analysis was performed 
using Analyse-lt, version 1.63, for all method comparison 
studies (Analyse-lt Software, Leeds, England).
R e s u l t s
The limit o f detection for each method was assessed 
and compared with the manufacturers* claimed values. The 
Access 2 had an average limit o f detection o f 0.4 ng/L with
a manufacturer's claim o f 1 ng/L; the ADV1A Centaur an 
average limit o f detection of 0.8 ng/L with a manufacturer's 
claim o f 2 ng/L; the AxSYM an average limit o f detection 
o f 9 ng/L with a manufacturer's claim o f 15 ng/L; and the 
E l70 an average limit o f detection of 3 ng/L with a manu­
facturer's claim o f 5 ng/L. Linearity for all 4 automated 
methods was assessed. All r values were more than 0.99 by 
linear regression analysis. The target value for each linear­
ity sample was calculated based on the samples with the 
lowest and highest concentrations within the analytic mea­
surement range for each method. All methods had a maxi­
mum average deviation from the target recovery of less 
than 10%. Imprecision for each method was determined 
using individual manufacturers' quality control materials as 
described. All methods demonstrated total imprecision of 
less than 6% ITable II.
Reference intervals were determined for each method 
using EDTA-anticoagulated plasma samples as described. The 
range of BNP concentrations observed for samples from 
healthy control subjects on the Access 2 was between 3 and 81 
ng/L with a 97.5% upper reference limit of 42 ng/L. The range 
of BNP concentrations observed on the ADV1A Centaur was 
between 0 and 80 ng/L, with a 97.5% upper reference limit of 
37 ng/L. The range of BNP concentrations observed on the 
AxSYM was from 0 to 144 ng/L, with a 97.5% upper refer­
ence limit of 79 ng/L. The range of NT-proBNP concentra­
tions observed for samples from healthy subjects on the E170 
was between 5 and 147 ng/L, with a 97.5% upper reference 
limit of 114 ng/L.
Method comparison studies using EDTA-anticoagulated 
plasma samples revealed varying differences in agreement 
between the automated methods and the Triage comparison 
method with slopes ranging from 0.77 to 8.9 and correlation
ITable II
Summary of Imprecision Data for Four Automated Natriuretic Peptide Assays"
Method/Sample Mean Concentration (ng/L)
Coefficient of Variation (% )
Within-Run Between-Run Between-Day Total
A ccess 2
L1 879 2.9 1.7 2.3 4.1
L2 408.0 1.6 2.2 1.3 3.0
L3 2,079.7 1.9 0.0 0.8 2.1
ADVIA Centaur
L1 44.5 2.3 3.8 0.0 4.4
L2 430.6 2.2 0.0 1.4 2.6
L3 1,571.8 1.8 0.4 1.7 2.5
AxSYM
L1 101.4 5.1 2.1 0.8 5.5
L2 423.2 4.4 1.4 2.2 5.2
L3 1,423.4 3.8 3.0 2.3 5.4
MODULAR ANALYTICS E170
L1 259.6 0.7 0.4 0.2 0.8
L2 6,039.2 0.4 0.7 0.0 0.8
For proprietary information, see the text.
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coefficients of 0.80 to 0.95 IFigure II. Passing-Bablok analy­
sis showed an average negative bias of 10 ng/L at the 100- 
ng/L cutoff between the Access 2 and the Triage comparison 
method. Analytic concordance data showed the Access 2 as 
having 95.9% agreement with the Triage with 3 false-positive 
and 5 false-negative results ITable 21.
Passing-Bablok analysis showed an average negative bias 
of 26 ng/L at the 100-ng/L cutoff between the ADVIA Centaur 
and the Triage comparison method. Concordance data showed 
the ADVIA Centaur as having 92.9% agreement with the 
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IFigure II Comparison of 4 automated natriuretic peptide 
assays with theTriage meter B-type natriuretic peptide (BNP) 
comparison method. A method comparison study was 
performed using 197 samples. The dotted line is the line of 
identity (x = y). Passing-Bablok regression analysis was 
performed and is indicated by a solid line. A, The Access 2 
BNP method gave a slope of 0.96 ± 0.02 and an intercept of 
-6  ± 4 ng/L; r = 0.95. B,The ADVIA Centaur BNP method 
gave a slope of 0.77 ± 0.02 and an intercept of -3  ± 3 ng/L; 
r = 0.92. C, The AxSYM BNP method gave a slope of 1.13 ± 
0.03 and an intercept o f -6  ± 4 ng/L; r=  0.94. D,The E170 
NT-proBNP method gave a slope of 8.9 ± 0.5 and an intercept 
of -225 ± 56 ng/L; r = 0.80. Nine samples that were noted to 
give higher NT-proBNP values are indicated by open circles 
and were excluded from final statistical analysis. For 
proprietary information, see the text.
The AxSYM demonstrated an average positive bias of 7 
ng/L at the 100-ng/L cutoff compared with the Triage method. 
The data showed the AxSYM as having 92.4% concordance 
agreement with 10 false-positive and 5 false-negative results 
compared with the Triage.
With the E170 NT-proBNP method, there were 9 statisti­
cal outliers, confirmed by repeated testing, that were excluded 
from Passing-Bablok analysis. Before exclusion of the out­
liers, Passing-Bablok regression analysis gave a slope of 9.7, 
an intercept of -298.6, and a correlation coefficient of 0.77. 
Passing-Bablok analysis also showed a high positive propor­
tional bias between the E170 and Triage methods. Analytic 
concordance results were calculated to show how the 2 meth­
ods compare. The E170 had 84.3% agreement with 26 false- 
positive and 5 false-negative results compared with the Triage 
method. Creatinine concentrations were measured, and 
glomerular filtration rates were calculated for the 9 outliers to 
determine whether the elevated NT-proBNP concentrations 
were associated with renal insufficiency. Creatinine concen­
trations were elevated for all 9 outliers, ranging in concentra­
tion from 1.5 to 6.4 mg/dL (133-566 nmol/L). The glomerular 
filtration rate was calculated for each of the 9 outliers using 
the Abbreviated Modification of Diet in Renal Disease study 
equation without correction for race because race was 
unknown.13 Values ranged from 10 to 39 mL/min per 1.73 m2.
In ITable 31, the results of epitope-mapping performed 
with BNPs and each of the 3 BNP methods are summarized.
ITable 21
Analytic Concordance of Four Automated Natriuretic Peptide 
Methods With the Triage Meter BNP Method*
Triage BNP
£100 ng/L <100 ng/L Total
Access 2 BNPt
>100 ng/L 142 3 145
<100 ng/L 5 47 52
Total 147 50
ADVIA Centaur BNP*
>100 ng/L 134 1 135
<100 ng/L 13 49 62
Total 147 50
AxSYM BNP^
>100 ng/L 142 10 152
<100 ng/L 5 40 45
Total 147 50
E170 NT-proBNPH
> Cutoff 142 26 168
< Cutoff 5 24 29
Total 147 50
BNP, B-type natriuretic peptide,
* Data are given as number of samples in each category. For proprietary information, 
see the text,
t Overall concordance with Triage, 189/197 (95.9%).
* Overall concordance with Triage, 183/197 (92.9%).
§ Overall concordance with Triage, 182/197 (92.4%).
I Overall concordance with Triage, 166/197 (84,3%). Age-appropriate cutoffs of <125 
ng/L for age younger than 75 years and <450 ng/L for 75 years or older were used.
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The Access 2 method recognized peptides 1-32, 3-32, 4-32, 
and 1-31. The ADVIA Centaur recognized peptides 1-32, 3­
32, 4-32, and 10-32. The AxSYM method recognized 1-32, 3­
32, and 4-32.
One additional experiment was conducted with the Triage 
meter and the Access 2 BNP methods. College of American 
Pathologists proficiency testing survey material was analyzed 
singly using 3 lots of Triage meter reagents and 1 lot of Access
2 reagent. Sample BNP-03 from 2003 gave Triage meter 
results of 241, 343, and 341 ng/L with each of the 3 lots of 
reagent, and the Access 2 method gave a result of 758 ng/L. 
Sample BNP-04 from 2003 gave Triage meter results of 908, 
1,200, and 973 ng/L with each of the 3 lots of reagent, and the 
Access 2 method gave a result of 2,679 ng/L.
D i s c u s s i o n
The limit o f detection for each method was lower than 
the manufacturers’ claimed limit of detection. Linearity was 
acceptable for all methods, with an r value o f more than 0.99 
by lineai' regression and recoveries for each point falling 
within ± 10% of the target value. The imprecision of all of 
the automated methods was adequate, with total coefficients 
o f variation of less than 6%. It is important to note that 
imprecision at or near the clinical decision threshold of 100 
ng/L for the Access 2, ADVIA Centaur, and AxSYM was 
acceptable. The Access 2 demonstrated a total coefficient of 
variation o f 4.1% at a mean concentration of 87.9 ng/L. The 
ADVIA Centaur demonstrated a total coefficient o f variation 
of 4.4% at a concentration o f 44.5 ng/L. The AxSYM 
demonstrated a total coefficient of variation o f 5.5% at a 
concentration of 101.4 ng/L. The lowest concentration 
assessed for imprecision on the E170 was 259.6 ng/L, which 
gave a total CV o f 0.8%. This concentration was higher than 
the manufacturer’s 125-ng/L cutoff for patients 74 years and 
younger but lower than the 450-ng/L cutoff for patients 75 
years and older.
The upper 97.5% reference limit for all methods fell 
below the manufacturers’ clinical decision thresholds. The 
AxSYM and E170 had upper limits that were only slightly 
lower than the manufacturers’ diagnostic cutoff values. The 
AxSYM had an upper reference limit of 79 ng/L with a diag­
nostic cutoff o f 100 ng/L, and the E170 had an upper reference 
limit of 114 ng/L with a diagnostic cutoff o f 125 ng/L. The 
Access 2 and ADVIA Centaur, however, had upper reference 
limits of 42 ng/L and 37 ng/L, respectively, that were much 
lower than the diagnostic cutoff o f 100 ng/L for each assay.
These results suggest that there will be intermethod differ­
ences in sensitivity and specificity. Of the BNP methods eval­
uated, the ADVIA Centaur would be expected to demonstrate 
the highest clinical specificity with the lowest sensitivity,
© American Society for Clinical Pathology
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ITable 31




Access 2 ADVIA Centaur AxSYM
1-32 82 126 106
3-32 69 126 118
4-32 159 175 164
10-32 <1 163 <1
1-31 87 <1 <1
Data are given as percentages. For proprietary information, see the text.
whereas the AxSYM would be expected to have the highest 
clinical sensitivity and the lowest clinical specificity. The 
E170 would be expected to have the highest clinical sensitivi­
ty with the lowest specificity of all methods, assuming 
approximately equal areas under the receiver operating char­
acteristic curves for BNP and NT-proBNP.14 A limitation of 
our reference interval study was that the age range of the 120 
reference subjects tested was 19 to 61 years with only 10% 
older than 45 years. The manufacturers’ clinical decision cutoff 
values were determined using samples from patients younger 
than 45 years to older than 75 years with heart failure and from 
age-matched healthy volunteers. No clinical information was 
available for the samples used in our study. Additional studies 
that compare the clinical sensitivity and specificity of these 
assays in the same group of patients with heart failure are 
needed to better understand the clinical implications of the 
assay differences we noted.
Method comparison results revealed differences between 
the automated methods and the Triage comparison method. 
The E170 showed the poorest agreement with the Triage 
method. The differences between the E170 and the Triage 
comparison method can be attributed to the fact that the 2 
methods measure different analytes: the Triage measures BNP, 
whereas the E170 measures NT-proBNP. Our slope of 8.9 was 
comparable to that in a previous report in which slopes ranged 
from 6 to 20 in a multicenter evaluation.9 There were 9 outliers 
by the E170 method, even after repeated testing, compared 
with the Triage comparison method. Although the cause for 
these outliers is uncertain, creatinine concentrations for these 
samples were all higher than 1.4 mg/dL (124 ^mol/L). The 
glomerular filtration rate was less than 40 mL/min per 1.73 m2 
for each subject from whom these samples were collected. This 
suggests that renal insufficiency might have contributed to ele­
vations in the NT-proBNP results that were out of proportion 
to BNP elevations in these subjects.2
The differences between the comparison method and the 
ADVIA Centaur might be due to calibration differences 
between the methods. The ADVIA Centaur yielded lower 
results with a substantial negative bias at the clinical decision
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threshold of 100 ng/L compared with the Triage method. We 
observed a slope of 0.77 that was comparable to a previous 
report showing a slope of 0.78 compared with the Triage 
meter.7 The ADVIA Centaur also demonstrated a higher num­
ber of false-negative results than the other methods compared 
with the Triage.
The AxSYM demonstrated good overall agreement with 
the Triage comparison method with a slope of 1.13 and corre­
lation coefficient of 0.94. It demonstrated concordance agree­
ment of 92.4% with fewer false-negative than false-positive 
results compared with the Triage method. We were unable to 
find published studies comparing the AxSYM and Triage 
methods. However, a comparison of the ADVIA Centaur and 
AxSYM methods found a slope of 1.55.8 Passing-Bablok 
analysis of the AxSYM vs ADVIA Centaur gave a slope of 
1.49, consistent with the findings of the previous study.
The Access 2 demonstrated the highest overall agreement 
with the Triage comparison method with a slope of 0.96 and a 
correlation coefficient of 0.95. It demonstrated the highest 
concordance agreement in comparison with the Triage with 
slightly fewer false-positive than false-negative results.
The differences between the ADVIA Centaur BNP 
method compared with the Triage, Access 2, and AxSYM 
BNP methods suggest that the ADVIA Centaur method is cal­
ibrated differently from the other 3 methods.
Our peptide immunoreactivity studies demonstrated sim­
ilarities and differences in the BNP epitopes recognized by 
each of the automated BNP immunoassays. It is noteworthy 
that the recovery of intact BNP (peptide 1-32) shown in Table
3 was not as one might have expected based on our other stud­
ies with EDTA-anticoagulated plasma samples. The ADVIA 
Centaur gave the highest recovery, whereas we would have 
predicted it would have had the lowest recovery. One explana­
tion is a matrix effect due to the artificial matrix that we used 
to prepare dilutions of the peptides. This matrix was chosen to 
minimize proteolytic degradation of the synthetic peptides in 
volumetric glassware. In future recovery and epitope-mapping 
studies, it may be more appropriate to use EDTA-anticoagu­
lated plasma, with protease inhibitors added, to minimize any 
matrix effects. Matrix issues also seem to be substantial with 
the 2003 College of American Pathologists BNP proficiency 
testing survey material. The Triage meter and the Access 2 
BNP methods gave results that differed by more than 100% 
for both survey samples. We presume that these 2 assays use 
the same antibodies because they have a common manufactur­
er, and with patient samples, they seem to be calibrated equiv­
alently. Even with proficiency testing survey materials pre­
pared in EDTA-anticoagulated plasma with protease 
inhibitors, as was the case for the 2 samples we studied, the 
matrix effects still can be substantial.
Matrix issues aside, our cross-reactivity studies suggest 
that each BNP immunoassay can recognize different circulating
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forms of BNP. The Access 2 and AxSYM methods recognize 
an epitope between amino acids 5 and 10 at the N-terminus of 
BNP. The ADVIA Centaur and AxSYM methods recognize an 
epitope at the C.-terminus of BNP. The AxSYM method 
reportedly uses a capture antibody that recognizes amino acids 
5 to 13 and a detection antibody that recognizes amino acids 
26 to 32 (written communication, J. Shih, PhD, Abbott 
Diagnostics, August 2004). The ADVIA Centaur assay seems 
to recognize the same epitopes as the Shionogi assay.4 As pre­
viously stated, des-SerPro-BNP (3-32) seems to be the major 
degradation product of BNP. All BNP assays that we evaluat­
ed recognize this product. Differences between BNP methods 
for specific samples could be due in pail to degradation of 
BNP in these samples.
Further characterization of endogenous BNP fragments 
and BNP degradation in EDTA-anticoagulated plasma and the 
exact epitopes recognized by all immunoassays would be use­
ful to better understand the large intermethod differences that 
are seen for a few samples. The clinical significance of these 
rare samples that show intermethod differences, if any, 
requires additional study as well.
All automated methods that we evaluated demonstrated 
acceptable analytic performance. Additional standardization 
efforts seem necessary to better harmonize the BNP methods. 
Also, because of differences in the epitopes recognized by 
each of the automated BNP methods, rare individual patient 
samples can show relatively large differences between meth­
ods, suggesting that these methods should not be interchanged 
for serial monitoring of individual patient conditions. The 
ADVIA Centaur method yields lower results on average than 
the other methods and likely has lower clinical sensitivity but 
higher specificity. The E170 NT-proBNP yields substantially 
higher results and cannot be used interchangeably with BNP 
methods. Further clinical studies need to be performed to 
compare the clinical sensitivity and specificity of the different 
automated methods using the same group of subjects.
C o n c l u s i o n s
All automated natriuretic peptide assays showed accept­
able analytic performance. The ADVIA Centaur method gave 
lower average results than the Access 2, AxSYM, and Triage 
meter methods. The E170 NT-proBNP method showed poor­
er overall analytic concordance than the other methods and 
gave a higher percentage of false-positive results compared 
with the Triage meter. BNP results are method-dependent, 
and a single predefined common medical decision point 
might not be appropriate. Each o f the BNP immunoassays 
uses antibody pairs that recognize different epitopes, which 
might contribute to assay discordance for individual samples. 
Matrix effects are known to be problematic with proficiency
© American Society for Clinical Pathology
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testing survey materials. They clearly are an issue for the 
Triage meter and Access 2 BNP methods, which use the same 
antibodies and similar calibrator materials.
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